0000899243-19-004317.txt : 20190220 0000899243-19-004317.hdr.sgml : 20190220 20190220194832 ACCESSION NUMBER: 0000899243-19-004317 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181119 FILED AS OF DATE: 20190220 DATE AS OF CHANGE: 20190220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: El-Hibri Fuad CENTRAL INDEX KEY: 0001380185 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 19620205 MAIL ADDRESS: STREET 1: 2273 RESEARCH BLVD, SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: 240-631-3200 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2018-11-19 2018-11-21 0 0001367644 Emergent BioSolutions Inc. EBS 0001380185 El-Hibri Fuad 400 PROFESSIONAL DRIVE, SUITE 400 GAITHERSBURG MD 20879 1 1 1 0 Chairman Common Stock 2018-11-19 4 M 0 20000 14.44 A 1508675 D Common Stock 2018-11-20 4 M 0 15173 14.44 A 1503848 D Common Stock 2018-11-26 4 M 0 25000 13.38 A 1513675 D Common Stock 2018-11-27 4 M 0 20832 13.38 A 1509507 D Common Stock 2018-11-27 4 S 0 20832 69.59 D 1488675 D Employee Stock Options (Right to Buy) 14.44 2018-11-19 4 M 0 20000 0.00 D 2019-03-12 Common Stock 20000 15173 D Employee Stock Options (Right to Buy) 14.44 2018-11-20 4 M 0 15173 0.00 D 2019-03-12 Common Stock 15173 0 D Employee Stock Options (Right to Buy) 13.38 2018-11-26 4 M 0 25000 0.00 D 2020-03-11 Common Stock 25000 20832 D Employee Stock Options (Right to Buy) 13.38 2018-11-27 4 M 0 20832 0.00 D 2020-03-11 Common Stock 20832 0 D All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on November 21, 2018, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. The number of shares of Common Stock directly beneficially owned by the Reporting Person reported on this amended Form 4 gives effect to the sales of Common Stock by the Reporting Person as reported on the Forms 4 filed with the SEC on November 21, 2018 and November 28, 2018, as applicable. The reported option exercises were inadvertently omitted from the original Form 4 filed with the SEC on November 28, 2018, which reported the sales of shares of Common Stock only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.31 to $70.32. The options vested in three equal installments on March 12, 2013, March 12, 2014 and March 12, 2015. The options vested in three equal installments on March 11, 2014, March 11, 2015 and March 11, 2016. /s/ Carl A. Valenstein, attorney-in-fact 2019-02-19